Biolife Solutions INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Casdin Capital, LLC and affiliated entities have reported a 9.7% beneficial ownership stake in BioLife Solutions, Inc. as of June 4, 2026.
NASDAQ
Invesco Ltd. has filed a Schedule 13G, reporting beneficial ownership of 4.9% of BioLife Solutions Inc. common stock as of March 31, 2026.
NASDAQ
The Vanguard Group reports zero beneficial ownership in BioLife Solutions Inc. common stock following an internal realignment.
NASDAQ
Invesco Ltd. has reported an 8.2% beneficial ownership stake in BioLife Solutions Inc. common stock as of December 31, 2025.
NASDAQ
T. Rowe Price Investment Management, Inc. has reported a significant beneficial ownership stake of 10.8% in BioLife Solutions Inc. common stock.
NASDAQ
SCHEDULE 13G: T. Rowe Price Boosts BioLife Solutions Stake to 8.9%
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 8.9% of BioLife Solutions Inc. common stock, totaling 4,246,706 shares.